Exane Derivatives’s CRISPR Therapeutics CRSP Stock Holding History

Exane Derivatives’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.22K	Hold	20	–	–	﹤0.01%	487
2022 Q1	$1.25K	Hold	20	–	–	﹤0.01%	789
2021 Q4	$1.52K	Sell	20 -900	-98%	-$78.6K	﹤0.01%	681
2021 Q3	$103K	Buy	920 +270	+42%	+$33.9K	0.02%	519
2021 Q2	$88.1K	Sell	650 -13	-2%	-$1.58K	0.02%	558
2021 Q1	$80.8K	Buy	+663	New	+$100K	0.02%	451

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Exane Derivatives's CRSP Position: Q2 2022 in Review

Exane Derivatives held its CRISPR Therapeutics (CRSP) position steady in Q2 2022 at 20 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #487.

Exane Derivatives first reported a position in CRSP in Q1 2021 and has held it in 6 quarters since. The position peaked at $103K in Q3 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Exane Derivatives held 20 shares of CRISPR Therapeutics worth $1.22K as of Q2 2022.
Exane Derivatives left its CRISPR Therapeutics share count unchanged in Q2 2022.
CRISPR Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #487 holding.
Exane Derivatives first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 6 quarters since.
Exane Derivatives's CRISPR Therapeutics position peaked at $103K in Q3 2021.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.